Drugs / 2nd Generation Designer T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00429078 | Jul 2007 → Apr 2011 | gastric cancer | Roger Williams Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2nd Generation Designer T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00429078 ↗ |
| Action | Deplete | “These modified cells are then re infused back into the participant so that they can attack and kill tumor cells.” NCT00429078 ↗ |
| Modality | Cell therapy | “Designer T cells are prepared by removing white blood cells from the participant, and then modifying these cells” NCT00429078 ↗ |